$CSTL
CASTLE BIOSCIENCES INC Stock $cstl

$cstl Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000144736221000251 Filed on November 08, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$25.04M	$23.48M	$17.30M
YoY Change	44.74%	54.27%	-1.91%
Cost Of Revenue	$4.597M	$4.500M	$2.670M
YoY Change	72.17%	81.82%	32.84%
Gross Profit	$20.44M	$18.98M	$14.63M
YoY Change	39.76%	48.92%	-6.39%
Gross Profit Margin	81.64%	80.83%	84.55%
Selling, General & Admin	$24.94M	$22.60M	$14.93M
YoY Change	67.02%	93.07%	51.88%
% of Gross Profit	121.98%	119.08%	102.08%
Research & Development	$9.372M	$7.500M	$4.560M
YoY Change	105.53%	145.26%	44.3%
% of Gross Profit	45.85%	39.53%	31.18%
Depreciation & Amortization	$1.451M	$395.0K	$160.0K
YoY Change	806.88%	231.93%	60.0%
% of Gross Profit	7.1%	2.08%	1.09%
Operating Expenses	$35.61M	$30.10M	$17.66M
YoY Change	101.66%	103.88%	35.74%
Operating Profit	-$15.17M	-$11.81M	-$3.034M
YoY Change	400.03%	202.85%	-216.07%
Interest Expense	$16.00K	$0.00	-$380.0K
YoY Change	-104.21%	-100.0%	-22.45%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$15.16M	-$11.79M	-$4.810M
YoY Change	215.07%	156.88%	-325.82%
Income Tax	-$8.725M	$0.00	$80.00K
% Of Pretax Income
Net Earnings	-$6.430M	-$11.79M	-$4.889M
YoY Change	31.52%	156.94%	-337.91%
Net Earnings / Revenue	-25.68%	-50.23%	-28.26%
Basic Earnings Per Share		-$0.47	-$0.23
Diluted Earnings Per Share	-$253.8K	-$0.47	-$0.23
COMMON SHARES
Basic Shares Outstanding	25.30M shares	25.29M shares	19.91M shares
Diluted Shares Outstanding		25.29M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$329.6M	$363.2M	$409.9M
YoY Change	-19.58%	98.35%	314.88%
Cash & Equivalents	$329.6M	$363.2M	$409.9M
Short-Term Investments	$0.00
Other Short-Term Assets	$4.807M	$5.500M	$4.800M
YoY Change	0.15%	48.65%	140.0%
Inventory	$2.021M	$2.375M	$2.217M
Prepaid Expenses
Receivables	$17.28M	$18.53M	$12.76M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$353.7M	$389.6M	$429.6M
YoY Change	-17.66%	93.76%	268.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.501M	$8.866M	$7.102M
YoY Change	33.78%	33.4%	244.76%
Goodwill	$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.715M	$1.728M	$1.536M
YoY Change	11.65%	5.49%	1037.78%
Total Long-Term Assets	$108.8M	$44.11M	$9.734M
YoY Change	1018.03%	372.81%	217.59%
TOTAL ASSETS
Total Short-Term Assets	$353.7M	$389.6M	$429.6M
Total Long-Term Assets	$108.8M	$44.11M	$9.734M
Total Assets	$462.6M	$433.7M	$439.3M
YoY Change	5.29%	106.13%	266.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.546M	$2.766M	$2.098M
YoY Change	21.35%	31.65%	12.49%
Accrued Expenses	$20.58M	$14.79M	$12.10M
YoY Change	70.08%	50.89%	61.33%
Deferred Revenue	$0.00	$2.999M	$6.615M
YoY Change	-100.0%	-64.08%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$105.0K		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$24.89M	$20.99M	$20.88M
YoY Change	19.21%	-30.58%	36.54%
LONG-TERM LIABILITIES
Long-Term Debt	$124.0K	$986.0K	$0.00
YoY Change		-92.08%	-100.0%
Other Long-Term Liabilities	$124.0K	$0.00	$1.026M
YoY Change	-87.91%	-100.0%	926.0%
Total Long-Term Liabilities	$124.0K	$986.0K	$1.026M
YoY Change	-87.91%	-92.08%	-94.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.89M	$20.99M	$20.88M
Total Long-Term Liabilities	$124.0K	$986.0K	$1.026M
Total Liabilities	$50.83M	$21.98M	$23.64M
YoY Change	115.05%	-49.86%	-31.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.77M	-$87.36M	-$62.50M
YoY Change	50.04%	51.64%	19.7%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$411.7M	$411.7M	$415.7M
YoY Change
Total Liabilities & Shareholders Equity	$462.6M	$433.7M	$439.3M
YoY Change	5.29%	106.13%	266.88%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$6.430M	-$11.79M	-$4.889M
YoY Change	31.52%	156.94%	-337.91%
Depreciation, Depletion And Amortization	$1.451M	$395.0K	$160.0K
YoY Change	806.88%	231.93%	60.0%
Cash From Operating Activities	-$2.781M	-$6.133M	-$430.0K
YoY Change	546.74%	107.9%	-109.56%
INVESTING ACTIVITIES
Capital Expenditures	-$893.0K	-$927.0K	-$590.0K
YoY Change	51.36%	-51.21%	68.57%
Acquisitions
YoY Change
Other Investing Activities	-$30.00M	$4.000K	$0.00
YoY Change
Cash From Investing Activities	-$30.89M	-$923.0K	-$590.0K
YoY Change	5135.42%	-51.42%	68.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	126.0K	1.894M	227.8M
YoY Change	-99.94%	-76.76%	98952.17%
NET CHANGE
Cash From Operating Activities	-2.781M	-6.133M	-430.0K
Cash From Investing Activities	-30.89M	-923.0K	-590.0K
Cash From Financing Activities	126.0K	1.894M	227.8M
Net Change In Cash	-33.54M	-5.162M	226.8M
YoY Change	-114.79%	-256.42%	5078.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.781M	-$6.133M	-$430.0K
Capital Expenditures	-$893.0K	-$927.0K	-$590.0K
Free Cash Flow	-$1.888M	-$5.206M	$160.0K
YoY Change	-1280.0%	395.81%	-96.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001447362
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38984
	dei	Entity Registrant Name EntityRegistrantName	CASTLE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0701774
	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 S. Friendswood Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 401
	dei	Entity Address City Or Town EntityAddressCityOrTown	Friendswood
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77546
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	788-9007
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	CSTL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25300343	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	363177000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409852000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18532000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12759000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	2375000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2217000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5500000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4766000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	389584000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	429594000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1410000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1096000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8866000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7102000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32104000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1728000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1536000	USD
CY2021Q3	us-gaap	Assets Assets	433692000	USD
CY2020Q4	us-gaap	Assets Assets	439328000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2766000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2098000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12120000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9108000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2999000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6615000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3108000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20993000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20876000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1735000	USD
CY2021Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	986000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1026000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	21979000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	23637000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25286546	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25286546	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24812487	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24812487	shares
CY2021Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499046000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478162000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87358000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62496000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	411713000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	433692000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	439328000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23475000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15217000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69046000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45350000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	4500000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	2475000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	11225000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	7012000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7500000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3058000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20201000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8675000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22595000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11703000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61578000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33173000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	694000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	950000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1882000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2021Q3	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	35289000	USD
CY2020Q3	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	19118000	USD
	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	93954000	USD
	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	48860000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11814000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3901000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24908000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3510000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	23000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	51000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	354000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	706000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	2239000	USD
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-11791000	USD
CY2020Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4589000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-24857000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5395000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11791000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11791000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4589000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4589000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24862000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24862000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5395000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5395000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25287000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19936000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25072000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18290000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25287000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19936000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25072000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18290000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	85113000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1577000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	603000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	570000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	87934000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1653000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69081000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1376000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	157622000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2118000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	292000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	693000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10423000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4589000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	166559000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4913000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	991000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1233000	USD
CY2021Q1	cstl	Adjustments To Additional Paid In Capital Stock Issuance Costs Adjustments Increase AdjustmentsToAdditionalPaidInCapitalStockIssuanceCostsAdjustmentsIncrease	39000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4280000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	418587000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4766000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1354000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8791000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	415916000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5210000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1523000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	855000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11791000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	411713000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24862000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5395000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1956000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	312000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14889000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5348000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	666000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	99000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6087000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1855000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	734000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1767000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	442000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	193000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1503000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	673000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	211000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3012000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	575000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5351000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8350000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	619000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1709000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	3000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	373000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16202000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10295000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2590000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4162000	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	33184000	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35768000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4160000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79504000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	336000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	3333000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3868000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	692000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1763000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1207000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5295000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78070000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46675000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84205000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	409852000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98845000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363177000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183050000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	190000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	54000	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	714000	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets and contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q2	cstl	Other Operating Income Loss Cares Act OtherOperatingIncomeLossCARESAct	1900000	USD
CY2021Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	8999000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	7175000	USD
	cstl	Contract With Customer Customer Payment Terms ContractWithCustomerCustomerPaymentTerms	P30D
CY2021Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	-92000	USD
CY2020Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1450000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	4130000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	223000	USD
CY2020Q2	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Payment Received CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived	8300000	USD
	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Recoupment Of Advanced Payment CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramRecoupmentOfAdvancedPayment	5351000	USD
	cstl	Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess	2698	claim
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3427000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2903000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3464000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2871000	shares
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11471000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8756000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2605000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1654000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8866000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7102000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	395000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	119000	USD
	us-gaap	Depreciation Depreciation	1006000	USD
	us-gaap	Depreciation Depreciation	312000	USD
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P11Y8M12D
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	694000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2753000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2753000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2761000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2753000	USD
CY2021Q3	cstl	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	20390000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32104000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1678000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1543000	USD
CY2021Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	617000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	276000	USD
CY2021Q3	cstl	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	431000	USD
CY2020Q4	cstl	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	348000	USD
CY2021Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	211000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	536000	USD
CY2021Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	116000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	151000	USD
CY2021Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	10000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	62000	USD
CY2021Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	45000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	139000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3108000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	37.00
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3369502	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	241600	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	67.79
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	362498	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	137873	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	30.97
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3110731	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	104585000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1068457	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.58
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M17D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	52271000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	56308000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5210000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2118000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14889000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5348000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D

Files In Submission

Name	View Source	Status
0001447362-21-000251-index-headers.html	Edgar Link	pending
0001447362-21-000251-index.html	Edgar Link	pending
0001447362-21-000251.txt	Edgar Link	pending
0001447362-21-000251-xbrl.zip	Edgar Link	pending
cstl-20210930.htm	Edgar Link	pending
cstl-20210930.xsd	Edgar Link	pending
cstl-20210930_cal.xml	Edgar Link	unprocessable
cstl-20210930_def.xml	Edgar Link	unprocessable
cstl-20210930_htm.xml	Edgar Link	completed
cstl-20210930_lab.xml	Edgar Link	unprocessable
cstl-20210930_pre.xml	Edgar Link	unprocessable
exhibit311-q32021.htm	Edgar Link	pending
exhibit312-q32021.htm	Edgar Link	pending
exhibit321-q32021.htm	Edgar Link	pending
exhibit322-q32021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSTL
CASTLE BIOSCIENCES INC Stock $cstl

2021 Q4 Form 10-Q Financial Statement

#000144736221000251 Filed on November 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL CASTLE BIOSCIENCES INC Stock $cstl

2021 Q4 Form 10-Q Financial Statement

#000144736221000251 Filed on November 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL
CASTLE BIOSCIENCES INC Stock $cstl